Compass Therapeutics (NASDAQ:CMPX) Sets New 1-Year High – Here’s What Happened

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $6.71 and last traded at $6.52, with a volume of 2383363 shares. The stock had previously closed at $6.40.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. William Blair initiated coverage on shares of Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating on the stock. JMP Securities set a $10.00 target price on Compass Therapeutics in a research note on Wednesday, December 3rd. Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Cantor Fitzgerald initiated coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “overweight” rating for the company. Finally, Compass Point set a $10.00 price objective on Compass Therapeutics in a research report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Stock Up 1.9%

The company has a market cap of $1.16 billion, a PE ratio of -14.49 and a beta of 1.46. The business has a 50-day simple moving average of $5.49 and a 200-day simple moving average of $4.30.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. On average, research analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC increased its stake in Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after buying an additional 6,951,666 shares in the last quarter. Vivo Capital LLC raised its holdings in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after acquiring an additional 3,502,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after acquiring an additional 2,212,794 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Compass Therapeutics by 280.4% during the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after purchasing an additional 2,386,367 shares during the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.